Go Deep
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,893 | -0.7 | 1.02 | 0.11 | 496.58 |
| Oct 2026 | 21,818 | -0.8 | 1.06 | 0.11 | 511.84 |
| Oct 2026 | 22,064 | -0.7 | 0.95 | 0.11 | 460.31 |
| Oct 2026 | 22,073 | -0.7 | 0.95 | 0.11 | 458.91 |
| Oct 2026 | 21,985 | -0.7 | 0.98 | 0.11 | 476.93 |
| Oct 2026 | 22,018 | -0.7 | 0.97 | 0.11 | 469.13 |
| Oct 2026 | 22,083 | -0.7 | 0.94 | 0.11 | 454.96 |
| Oct 2026 | 22,101 | -0.6 | 0.94 | 0.11 | 453.06 |
Aligos Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 27,778,000.0 | 2,830,000.0 | 169,000.0 | 741,000.0 |
| Net Profit | -1,504,000.0 | -23,040,000.0 | -19,881,000.0 | -31,537,000.0 |
| EPS | -0.1 | -2.2 | -1.9 | -3.0 |
Aligos Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 2,186,000.0 | 3,945,000.0 | 15,529,000.0 | 13,907,000.0 | — |
| Net Profit | -24,193,000.0 | -131,211,000.0 | -87,679,000.0 | -96,046,000.0 | — |
| EPS | -2.5 | -20.9 | -34.2 | -56.2 | — |
Aligos Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 88,533,000.0 | 70,094,000.0 | 151,527,000.0 | 146,693,000.0 | — |
| Total Liabilities | 34,988,000.0 | 99,067,000.0 | 59,447,000.0 | 42,793,000.0 | — |
| Total Equity | 53,545,000.0 | -28,973,000.0 | 92,080,000.0 | 103,900,000.0 | — |
Owes vs Owns
Aligos Therapeutics, Inc. owed $0.52 for every $1 it owned in Jun 2026, up from $0.29 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.52× | 0.40× | 1.41× | 0.39× | 0.29× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Aligos Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 87.9%Fixed assets (tangible) 5.6%Other assets 6.5%
How it's funded — Dec 2025
Short-term debt 4.2%Long-term debt 1.7%Payables 4.5%Other liabilities 29.1%Shareholders' equity 60.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 77.8 | 56.9 | 135.7 | 125.8 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 5.0 | 7.3 | 9.8 | 12.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 5.7 | 5.8 | 6.0 | 8.4 |
| Liabilities & equity | ||||
| Short-term debt | 3.7 | 3.5 | 3.2 | 3.1 |
| Long-term debt | 1.5 | 4.9 | 7.9 | 9.4 |
| Payables | 4.0 | 2.6 | 2.5 | 4.7 |
| Other liabilities | 25.8 | 88.1 | 45.8 | 25.5 |
| Shareholders' equity | 53.5 | -29.0 | 92.1 | 103.9 |
| Net tangible assets | 53.5 | -29.0 | 92.1 | 103.9 |
Aligos Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -82,503,000.0 | -80,743,000.0 | -78,997,000.0 | -79,389,000.0 | — |
| Investing Activities | -37,826,000.0 | -18,279,000.0 | 44,981,000.0 | -26,293,000.0 | — |
| Financing Activities | 101,635,000.0 | 355,000.0 | 88,328,000.0 | 164,000.0 | — |